Premium
Cannabinoid Receptor‐Regulated Cyclic AMP Accumulation in the Rat Striatum
Author(s) -
BidautRussell Michelle,
Hewlett Allyn C.
Publication year - 1991
Publication title -
journal of neurochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.75
H-Index - 229
eISSN - 1471-4159
pISSN - 0022-3042
DOI - 10.1111/j.1471-4159.1991.tb06379.x
Subject(s) - cannabinoid , dopaminergic , agonist , chemistry , (+) naloxone , pharmacology , dopamine , cannabinoid receptor , opioid , medicine , endocrinology , receptor , biology , biochemistry
: The present study demonstrates that desacetyllevo‐nantradol, a synthetic cannabinoid analog, reduces cyclic AMP levels in rat striatal slices stimulated with vasoactive intestinal peptide or SKF 38393, a D 1 ‐dopamine agonist. Desacetyllevonantradol and the D 2 agonist LY 171555 both inhibited D 1 ‐stimulated cyclic AMP accumulation in the striatum. Spipcrone, a specific D 2 ‐dopamine antagonist, fully reversed the inhibitory effect of LY 171555 but not that of desacetyllevonantradol, indicating that this cannabinoid response is not occurring through a D 2 ‐dopaminergic mechanism. Morphine also inhibited cyclic AMP accumulation in striatal slices stimulated with either SKF 38393 or vasoactive intestinal peptide. Naloxone, an opioid antagonist, fully reversed the effect of morphine but not that of desacetyllev‐onantradol, indicating that cannabinoid drugs are not acting via a mechanism involving opioid receptors. The response to maximally effective concentrations of desacetyllevonan‐tradol was not additive to that of maximally effective concentrations of either morphine or LY 171555, suggesting that dopaminergic, opioid, and cannabinoid receptors may be present on the same populations of cells.